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Purpose: Venous malformations (VMs) are common congenital benign lesions characterized by slow progression.
However, intralesional hemorrhage can result in sudden enlargement of the lesions, which, though uncommon clinically,
brings difficulties in diagnosis and treatment. The purpose of this study is to explore the clinical features and diagnosis
modality of intralesional hemorrhage in VMs and present our experience with embolosclerotherapy.
Methods: A series of 16 patients were recruited fromMay 2003 to February 2007, of which fifteen were males and one was
female, aged from five months to 40 years (mean, 11.4 years). The anatomic sites affected included cheek (n  6), upper
lid (n 3), neck (n 3), parotid region (n 2), temple (n 1), and upper limb (n 1). The period of enlargement varied
from one day to 25 days (mean, 8.4 days). Diagnostic needle aspiration was performed to analyze the internal contents
of themasses bymacroscopic observation.Magnetic resonance imaging (MRI) was applied to determine the size, location,
and extent of the lesions. Two patients received percutaneous venography. Routine blood testing was carried out in all
cases. A combination of absolute alcohol and Bleomycin A5 embolosclerotherapy was administered to the patients. The
procedure was repeated after 6 to 8 weeks. Outcomes were assessed by MRI measurement and pre and post treatment
color photos.
Results: All the patients were diagnosed with hemorrhage in VMs. The volume of the localized lesions varied from
3 cm  2 cm  1 cm to 8 cm  5 cm  3 cm. Fourteen patients received embolosclerotherapy in one (n  10) or two
(n  4) sessions. Two cases were not treated and the lesions regressed spontaneously with detectable residual lesions.
After a mean follow-up of 25 months (range, 3 to 40 months), treatment was considered effective in 12 patients. The
complications were minimal including temporary swelling in 14 treated patients and mild fever in two patients.
Conclusion: Intralesional hemorrhage in VMs should be distinguished from other lesions in the head and neck region.
Diagnostic puncture and MRI are essential for accurate diagnosis. Percutaneous embolosclerotherapy using a combina-
tion of absolute ethanol and Bleomycin A5 is a safe and effective treatment of choice. ( J Vasc Surg 2009;49:429-34.)Venous malformations (VMs) are common congenital
anomalies of vascular morphogenesis. The lesions grow
commensurately with the child’s development and do not
show involution.1,2 It is uncommon for the lesions to
expand suddenly within a few days. However, if intrale-
sional hemorrhage occurs, the lesions may enlarge rapidly,
which is quite dissimilar to their natural history. Misdiag-
nosis or improper treatment may occur if attending physi-
cians are not familiar with this situation.
In the past four years, a total of 16 patients with
intralesional hemorrhage in VMs were treated in our de-
partment. We performed a retrospective study of those
cases and confirmed that clinical history, physical examina-
tion, diagnostic needle aspiration, and magnetic resonance
imaging (MRI) findings were essential to establish a correct
diagnosis. Meanwhile, percutaneous embolosclerotherapy
using a combination of absolute ethanol and Bleomycin A5
has been performed in our department for the treatment of
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doi:10.1016/j.jvs.2008.08.051common VMs (VMs without hemorrhage). The safety and
effectiveness of this therapy has been well established.3 Our
aim was to extend the use of this method to treat patients
with intralesional hemorrhage in VMs.
The purpose of this study was to explore the clinical
features, diagnosis, and differential diagnosis of intrale-
sional hemorrhage in VMs and develop an effective treat-
ment method.
PATIENTS AND METHODS
Patients. From May 2003 to February 2007, 16 pa-
tients with intralesional hemorrhage in VMs were included
in this study. Those included 15 males and 1 female aged
from 5 months to 40 years (mean, 11.4 years). The ana-
tomic sites affected included cheek (n  6), upper lid (n 
3), neck (n  3), parotid region (n  2), temple (n  1),
and upper limb (n  1). The period of enlargement varied
from 1 day to 25 days (mean, 8.4 days). Six patients pro-
vided specific trauma histories (blunt trauma in three cases and
intensive joint movements in the other three cases). Three
patients complained of pre-existing masses before the onset of
hemorrhage.
At their first visit to the department, diagnostic needle
aspiration was performed in all patients to analyze the
internal contents of the masses by macroscopic observation.
MRI was applied in defining the size, location, and extent
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raphy. Routine blood testing was carried out in all cases.
Treatment techniques. Written informed consent
was obtained from the patients or their parents before
treatment. The first procedure began when the lesions
stopped expanding and were stabilized for one week. Six
pediatric patients were treated under general anesthesia and
the other patients without anesthesia.
After preparation of the treatment site with povidone-
iodine, 1-2 mL blood was aspirated out of the lesion by a 5
mL-syringe to check for blood again. Then a direct punc-
ture was performed using 21-gauge needles. At each ses-
sion, 2-6 injection sites were needed according to the
size of the lesions. Once the blood returned, 1-3 mL
absolute alcohol was injected first, followed by a maxi-
mum of 8 mg of bleomycin A5 after 1 to 2 minutes (8 mg
dissolved in 4 mL 0.9% sodium chloride). The maximum
dose in a single procedure was 0.1 mL/kg for absolute
alcohol and 0.2 mg/kg for Bleomycin A5.
The treatment was repeated if there was detectable
residual mass and confirmed by a direct puncture (venous
blood return). The interval between two procedures was
6-8 weeks.
Outcome evaluation. MRI and pre- and post-treatment
color photos were applied in outcome evaluation. Due to
the limited number of cases, we used two categories for
outcome evaluation. The treatment was considered effec-
tive if the volume of the lesion was reduced 75% (mea-
sured by MRI parameters) or significant improvements in
appearance were observed and the patient requested no
further treatment. The treatment was considered ineffec-
tive if the volume of the lesion was reduced 75% or the
patient was not satisfied with the improvements in appear-
ance.
RESULTS
All the patients were diagnosed with intralesional hem-
orrhage in VMs (Fig 1). No abnormal hematologic findings
Fig 1. a, A 14-year-old boy with a lesion in the left chee
was revealed in MRI (arrow). d,Normal venous blood wa
diagnosis of intralesional hemorrhage in venous malformwere observed in routine blood testing. Fifteen patientsdeveloped localized lesions and 1 patient had an infiltrating
lesion. The volume of the localized lesions varied from 3 cm
2 cm  1 cm to 8 cm  5 cm  3 cm measured by MRI.
The infiltrating lesion was not measured.
Fourteen patients received embolosclerotherapy with
one (n  10) or two (n  4) procedures. At a mean
follow-up of 25 months (range, 3-40 months), treatment
was considered effective in 12 patients. Percentage of vol-
ume reduction was 82% to 100% (mean, 93%).The patients
recovered to nearly normal appearance and asked for no
further treatment. Three cases manifested complete resolu-
tion of the lesions (Fig 2). In two infantile cases with lesions
involving upper eyelids, the treatment was ineffective due
to unsatisfactory appearance improvements with a clear-
ance rate of 50% and their parents declined further treat-
ment. Patients’ follow-up showed stable lesions.
The two patients who were not treated were monitored
for 4 years and 4 months respectively. The lesions resolved
spontaneously after 2 months, but the residual lesions
exhibited typical VM features, which corroborated our
initial diagnosis (Fig 3).
The complications were generally minimal. All treated
patients experienced a degree of local swelling that re-
gressed without any therapy after 5 to 10 days. Two pa-
tients complained of mild fever that disappeared after 2
days. No major or permanent complications occurred.
There was no clinical or MRI evidence of recurrence in the
treated cases.
DISCUSSION
Pathogenesis of intralesional hemorrhage in VMs.
Even though the pathogenesis of intralesional hemorrhage
in VMs is not well recognized, it may have a close relation-
ship with the abnormal structure of the vascular wall. The
VMs are formed by thin-walled channels, deficient in
smooth muscle cells and lined by a single layer of endothe-
lium.4 There are slit-like or interconnected channels dis-
secting through normal tissues. These veins will dilate over
Two years after one treatment. c, A small residual lesion
irated from the residual lesion that was supportive for the
s.k. b,
s asptime because of repeated engorgement.5
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early anomalous veins the blood flow is slow with stable
hemodynamics. During puberty or pregnancy, the lesions
tend to grow more rapidly, which is stimulated by hor-
monal effects. However, such sudden enlargement as we
have described in this study may not happen during puberty
or pregnancy.
Trauma is considered to be one of the important factors
contributing to sudden growth of the lesions. Intensive
movements of the joints have the same effects as blunt
trauma, such as temporomandibular joint, shoulder joint,
or elbow joint. The clear history of intensive joint move-
ments in our three cases proved this. The blood escapes out
of the ruptured veins and accumulates in the adjacent
venous sinuses. Not all the VMs have sufficient peripheral
drainage according to their anatomy and hemodynamic
Fig 2. A 3-year-old boy with a lesion in the left cheek. T
hemorrhage. He had no trauma history. a, Before treatm
imaging revealed a well-defined margin of inhomogeno
resolved completely 5 months later.features.6 Such blood flow disturbances may change thestable hemodynamics and peripheral drainage of the VMs
so that more veins are perfused and dilated rapidly in a short
time. The duration of enlargement varied from one to 25
days in our study. If not treated, the expanded lesions
would regress gradually, but residual lesions were notice-
able. In this study, only 6 patients provided clear trauma
histories; the bleeding etiology of the other cases was
unknown. The normal routine blood testing excluded
hematologic disease that may cause bleeding on the
whole.
Diagnosis anddifferential diagnosis. Final diagnosis of
the intralesional hemorrhage in venous malformations relied
on the combination of the clinical history, clinical presenta-
tion, diagnostic needle aspiration, and MRI findings.
Clinical history is important to the diagnosis for a
sudden enlarged mass. The following three types of signs
ident bruise on his left cheek was a sign of subcutaneous
b, Five months after one session. c, Magnetic resonance
gh-singal intensity area in the left cheek. d, The lesionhe ev
ent.
us hicould be more supportive: clear history of direct blunt
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lesions proven to be VM by long-term follow-up.
On physical examination, the lesion presented a local-
ized, prominent, and tense mass at palpation under normal
or purple skin. The purple skin was an obvious symptom of
subcutaneous hemorrhage. No pulsate or thrill could be
detected.
Diagnostic needle aspiration was useful to identify
whether the lesion was formed by vascular channels. Even
without the negative pressure aspiration by a syringe, the
blood could flow out from the end of the needle easily. By
macroscopic observation, except for being slightly darker in
color, the blood had the same characteristics as normal
venous blood without any suspicious components. These
findings do not occur in solid or cystic tumors.
MRI plays a leading role in the diagnosis of different
type of vascular anomalies. MRI is powerful in its ability to
delineate the extent of the lesions and the relationship to
the adjacent tissues and organs,7,8 which was the most
important imaging modality to guide our treatment. In the
case of an infiltrating lesion, phleboliths were revealed by
MRI that made the diagnosis more convincing. However,
it is difficult to distinguish the bleeding VMs from common
VMs (VMs without intralesional bleeding), especially large
lesions, by MRI. However, MRI can be used to exclude
other type of tumors.
The most confusing lesions are intralesional bleeding in
lymphangiomas. MRI showed a tumor with sharp border,
homogenous intensity, a fluid-fluid level, and no signal
enhancement. By needle aspiration, the blood is brown to
black, viscous but not clotting. In two patients, we per-
formed percutaneous direct puncture phlebography to see
whether the bleeding was in VMs or in lymphangiomas.
The lesion was proved to be VM due to the emergence of
Fig 3. a, A 16-year-old boy had an extensive mass invol
intense exercises. He was not treated. b, Four months l
Small and hard nodules could be felt under the skin (
phleboliths within the lesion (arrow).draining veins. Phlebography is used as a road map to guidethe treatment of the VMs with high risk, while rarely
needed for the differential diagnosis. Other tumors in the
head and neck region with similar presentations to bleeding
VMs include false aneurysm, branchial cleft cyst, and pa-
rotid cyst. False aneurysms may arise following traumatic
damage to an artery and are comprised of a slowly expand-
ing blood-filled cavity, which is held around the artery by
connective tissue. But generally it is a mass with pulsate and
thrill, which is similar to arteriovenous malformations
(AVMs) but not to VMs. Branchial cleft cysts and parotid
cysts can be distinguished by the findings of cholesterol
crystal and positive amylase test for aspirated liquid.
Evaluation of combination embolosclerotherapy.
In recent years, absolute alcohol has been the most com-
monly used liquid agent for the percutaneous embolization
of VMs.9 As absolute alcohol can result in severe endothe-
lial denudation and thrombosis immediately, it is the only
known and clinically tested effective scleroagent to be able
to abrogate endothelial cells, with the prospect of a “cure”
in selected cases.10-12 A response rate of 74% to 91% with
limited to no recurrence has been reported.10,11,13,14 Bleo-
mycin A5 is a refined ingredient from Bleomycin with more
potent antitumor abilities. Bleomycin can produce a scle-
rosing effect on the endothelial cells of the vessels. Minor
complications were reported in the treatment of VMs.15
Since 2002, we have used the two sclerosing agents in
combination in our department. This combination therapy
has been proven to be very effective with only minor
complications when treating common VMs.3 Here we have
reported that this method was also a treatment of choice for
VMs with intralesional bleeding. Most of the bleeding
lesions were limited with predictable favorable outcomes.
However, because the bleeding lesions were different from
his left neck. The mass enlarged abruptly overnight after
the mass had regressed and previous lesion still existed.
). c, Magnetic resonance imaging revealed numerousving
ater,
arrownon-bleeding ones after all, we could not tell if our method
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further study is warranted.
CONCLUSION
Intralesional hemorrhage in VMs is uncommon. Accu-
rate diagnosis and differential diagnosis should be based on
the history, clinical presentations, diagnositic needle aspi-
ration, and MRI findings. Percutaneous absolute ethanol
and Bleomycin A5 embolosclerotherapy is a safe and effec-
tive treatment of choice.
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In this article, the authors describe the successful management
of 16 patients with relatively sudden enlargement of a venous
malformation (VM) due to acute hemorrhage. This represents a
small subset of patients with VMs since the majority of VMs do not
develop intra-lesion hemorrhage. The authors report good results
using a combination of ethanol and bleomycin as the sclerosing
agent. While the use of the powerful sclerosing agent absolute
ethanol is quite well accepted for treating more aggressive arterio-
venous malformations, its use in VM is more limited. This is
because of serious potential complications reported with its use,
including acute complications of nerve palsy or even cardiopulmo-
nary arrest.1,2 Therefore, many have begun to consider the use of
less dangerous sclerosing agents, such as detergent-based foam,
especially for less aggressive VMs, including those with transder-
mal extension in which there is a higher risk for complications from
ethanol injection. Although foam sclerotherapy is likely less effec-
tive than ethanol, the complication rate is lower, and if VMs recur,
or are only partially treated initially, they can be re-treated withThe authors attempted to reduce the risk involved with etha-
nol injection of the VM by mixing it with bleomycin. However, it
is difficult to judge the contribution of bleomycin to the overall
treatment outcome since the ethanol was given first to block the
draining veins; regardless of its amount, there is substantial risk of
the vascular spasm induced by the ethanol before bleomycin begins
to work, reducing its effective contact with the endothelial cells.
Bleomycin was used extensively to various lymphatic malfor-
mations (LMs) with excellent result for the macrocystic lesions in
particular.3,4 It still remains a major option when OK-432 (Chugai
Pharmaceutical, Tokyo, Japan), also known as picibanil, which is
made with attenuated streptococcal exotoxin, is not available for
the LM.5,6 However, we have found bleomycin is generally less
effective when the LM is mixed with the VM. Furthermore, the
potential concern for pulmonary fibrosis as a long-term complica-
tion of bleomycin remains to be answered especially when it is
injected to the VM/venous system. This potential long-term con-
cern has led us not to use bleomycin for VM treatment.
